Although direct inhibitors of the NF-κB signaling pathway are not yet available for CLL treatment, the MURANO and the CLL14 trials document that BCL2 inhibition may circumvent and overcome the activation of NF-κB that is due to BIRC3 disruption in CLL. Here, BIRC3 is linked to B-cell chronic lymphocytic leukemia.